<DOC>
	<DOCNO>NCT00956072</DOCNO>
	<brief_summary>RATIONALE : Surgery may remove residual disease patient gastrointestinal stromal tumor respond imatinib mesylate . It yet know whether surgery effective continue imatinib mesylate treat patient metastatic gastrointestinal stromal tumor . PURPOSE : This randomized phase III trial study give imatinib mesylate therapy together surgery see well work compare imatinib mesylate alone treat patient metastatic gastrointestinal stromal tumor respond imatinib mesylate .</brief_summary>
	<brief_title>Imatinib Mesylate With Without Surgery Treating Patients With Metastatic Gastrointestinal Stromal Tumor That Responding Imatinib Mesylate</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate whether surgery residual disease improve progression-free survival patient metastatic gastrointestinal stromal tumor respond imatinib mesylate . Secondary - Correlate pharmacokinetics imatinib mesylate metabolite randomization . OUTLINE : This multicenter study . Patients stratify accord center , site tumor origin ( stomach v small bowel v others ) , site metastasis ( liver vs abdominal cavity v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo surgery residual disease . Patients resume imatinib mesylate therapy accord standard care soon possible surgery ( soon patient restarts take oral feeding ) . - Arm II : Patients receive imatinib mesylate therapy accord standard care . Patients complete quality life questionnaire baseline ; immediately hospital discharge ( arm I ) ; 5 , 11 , 23 month . Blood sample may collect pharmacokinetic study . After completion study therapy , patient follow every 3 month 5 year every 6 month .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm gastrointestinal stromal tumor express CD117+ document mutation KIT PDGFRA gene Metastatic disease ( liver and/or abdominal cavity ) No extraabdominal metastasis Measurable disease accord RECIST criterion Achieved complete response , partial response , stable disease without progression since start imatinib mesylate therapy , document accord RECIST Underwent 612 month treatment imatinib mesylate standard care within clinical study ( surgery feasible end 12th month imatinib mesylate onset ) Surgically resectable residual disease assess CT scan and/or MRI within past 14 day PATIENT CHARACTERISTICS : WHO performance status 01 ANC &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin ≥ 9 g/dL Creatinine &lt; 120 μmol/L Albumin &gt; 25 g/L Total bilirubin &lt; 2 time upper limit normal ( ULN ) AST ALT &lt; 2.5 time ULN ( &lt; 5 ULN case liver metastasis ) Alkaline phosphatase &lt; 2.5 time ULN ( &lt; 5 ULN case bone liver metastasis ) Negative pregnancy test within past 14 day Fertile patient must use effective contraception No uncontrolled hypertension ( diastolic BP &gt; 95 mm Hg systolic BP &gt; 170 mm Hg ) No myocardial infarction , unstable , uncontrolled cardiac disease within past 6 month No history arterial thrombosis deep vein thrombosis within past year No bleed diathesis , coagulopathy , major bleed within past 6 month No severe and/or uncontrolled concurrent medical disease , include follow condition : Diabetes Chronic renal disease Liver disease , include chronic viral hepatitis judge risk reactivation Active infection , include HIV infection No prior malignancy ( situ cervical cancer , situ melanoma , basal cell squamous cell cancer skin ) unless treat curative intent without evidence disease least 3 year No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior adjuvant neoadjuvant imatinib mesylate tyrosine kinase inhibitor No coumadintype anticoagulant &gt; 2mg/day within past 7 day No major surgery within past 28 day No medication interact moderately strongly CYP3A system within past 14 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>gastrointestinal stromal tumor</keyword>
</DOC>